Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma.

Mathew Thomas V, Bindal P, Vredenburgh JJ.

Case Rep Oncol. 2019 Jan 30;12(1):126-130. doi: 10.1159/000496984. eCollection 2019 Jan-Apr.

2.

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.

Affronti ML, Woodring S, Peters KB, Herndon JE 2nd, McSherry F, Healy PN, Desjardins A, Vredenburgh JJ, Friedman HS.

Ther Clin Risk Manag. 2016 Dec 23;13:33-40. doi: 10.2147/TCRM.S122480. eCollection 2017.

4.
5.

Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).

Affronti ML, Woodring S, Allen K, Kirkpatrick J, Peters KB, Herndon JE 2nd, McSherry F, Healy PN, Desjardins A, Vredenburgh JJ, Friedman HS.

Support Care Cancer. 2016 Oct;24(10):4365-75. doi: 10.1007/s00520-016-3276-1. Epub 2016 Jun 6.

PMID:
27271867
6.

Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic astrocytomas in adults with NF1.

Strowd RE 3rd, Rodriguez FJ, McLendon RE, Vredenburgh JJ, Chance AB, Jallo G, Olivi A, Ahn ES, Blakeley JO.

Am J Med Genet A. 2016 Jun;170(6):1455-61. doi: 10.1002/ajmg.a.37622. Epub 2016 Mar 14.

7.

Dual HER2 Blockade in Non-Small Cell Lung Cancer Harboring a HER2 Mutation.

Mar N, Vredenburgh JJ.

Conn Med. 2015 Oct;79(9):531-5.

PMID:
26630704
8.

CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the Limitations.

Mar N, Desjardins A, Vredenburgh JJ.

Clin Cancer Res. 2015 Oct 1;21(19):4248-50. doi: 10.1158/1078-0432.CCR-15-1381.

9.

Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.

Peters KB, Lou E, Desjardins A, Reardon DA, Lipp ES, Miller E, Herndon JE 2nd, McSherry F, Friedman HS, Vredenburgh JJ.

Oncologist. 2015 Jul;20(7):727-8. doi: 10.1634/theoncologist.2015-0135. Epub 2015 May 29.

10.

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.

Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE 2nd, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Sampson JH.

Nature. 2015 Mar 19;519(7543):366-9. doi: 10.1038/nature14320. Epub 2015 Mar 11.

11.

Targeting HER2 in the treatment of non-small cell lung cancer.

Mar N, Vredenburgh JJ, Wasser JS.

Lung Cancer. 2015 Mar;87(3):220-5. doi: 10.1016/j.lungcan.2014.12.018. Epub 2015 Jan 8. Review.

PMID:
25601485
12.

Blue toes and a new pair of shoes--challenges in diagnosis and treatment of acute myelogenous leukemia.

Mar N, Gorgan MA, Dailey ME, Vredenburgh JJ.

Am J Hematol. 2013 Dec;88(12):1090-3. doi: 10.1002/ajh.23563. Epub 2013 Oct 22. No abstract available.

13.

Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.

Cabrera AR, Cuneo KC, Desjardins A, Sampson JH, McSherry F, Herndon JE 2nd, Peters KB, Allen K, Hoang JK, Chang Z, Craciunescu O, Vredenburgh JJ, Friedman HS, Kirkpatrick JP.

Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):873-9. doi: 10.1016/j.ijrobp.2013.04.029. Epub 2013 May 29.

PMID:
23725997
14.

O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.

Jiang X, Reardon DA, Desjardins A, Vredenburgh JJ, Quinn JA, Austin AD, Herndon JE 2nd, McLendon RE, Friedman HS.

J Neurooncol. 2013 Aug;114(1):135-40. doi: 10.1007/s11060-013-1162-y. Epub 2013 May 18.

PMID:
23686298
15.

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.

Lou E, Peters KB, Sumrall AL, Desjardins A, Reardon DA, Lipp ES, Herndon JE 2nd, Coan A, Bailey L, Turner S, Friedman HS, Vredenburgh JJ.

Cancer Med. 2013 Apr;2(2):185-95. doi: 10.1002/cam4.58. Epub 2013 Jan 24.

16.

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.

Reardon DA, Herndon JE 2nd, Peters KB, Desjardins A, Coan A, Lou E, Sumrall AL, Turner S, Lipp ES, Sathornsumetee S, Rich JN, Sampson JH, Friedman AH, Boulton ST, Bigner DD, Friedman HS, Vredenburgh JJ.

Br J Cancer. 2012 Oct 23;107(9):1481-7. doi: 10.1038/bjc.2012.415. Epub 2012 Oct 4.

17.

Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme.

Cabrera AR, Cuneo KC, Vredenburgh JJ, Sampson JH, Kirkpatrick JP.

J Natl Compr Canc Netw. 2012 Jun 1;10(6):695-9.

PMID:
22679114
18.

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.

Lou E, Sumrall AL, Turner S, Peters KB, Desjardins A, Vredenburgh JJ, McLendon RE, Herndon JE 2nd, McSherry F, Norfleet J, Friedman HS, Reardon DA.

J Neurooncol. 2012 Aug;109(1):63-70. doi: 10.1007/s11060-012-0861-0. Epub 2012 Apr 26.

19.

Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.

Reardon DA, Vredenburgh JJ, Desjardins A, Peters KB, Sathornsumetee S, Threatt S, Sampson JH, Herndon JE 2nd, Coan A, McSherry F, Rich JN, McLendon RE, Zhang S, Friedman HS.

J Neurooncol. 2012 Jul;108(3):499-506. doi: 10.1007/s11060-012-0848-x. Epub 2012 Mar 10.

20.

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.

Sampson JH, Schmittling RJ, Archer GE, Congdon KL, Nair SK, Reap EA, Desjardins A, Friedman AH, Friedman HS, Herndon JE 2nd, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Mitchell DA.

PLoS One. 2012;7(2):e31046. doi: 10.1371/journal.pone.0031046. Epub 2012 Feb 27.

21.

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.

Reardon DA, Desjardins A, Vredenburgh JJ, Herndon JE 2nd, Coan A, Gururangan S, Peters KB, McLendon R, Sathornsumetee S, Rich JN, Lipp ES, Janney D, Friedman HS.

Cancer. 2012 Oct 1;118(19):4759-67. doi: 10.1002/cncr.26541. Epub 2012 Feb 27.

22.

Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.

Reardon DA, Herndon JE 2nd, Peters K, Desjardins A, Coan A, Lou E, Sumrall A, Turner S, Sathornsumetee S, Rich JN, Boulton S, Lipp ES, Friedman HS, Vredenburgh JJ.

J Neurooncol. 2012 Mar;107(1):213-21. doi: 10.1007/s11060-011-0740-0. Epub 2011 Oct 14.

23.

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.

Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS.

J Neurooncol. 2012 Mar;107(1):155-64. doi: 10.1007/s11060-011-0722-2. Epub 2011 Oct 11.

24.

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.

Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE 2nd, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS.

J Neurooncol. 2012 Jan;106(2):409-15. doi: 10.1007/s11060-011-0687-1. Epub 2011 Sep 22.

25.

Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.

Lou E, Turner S, Sumrall A, Reardon DA, Desjardins A, Peters KB, Sampson JH, Friedman HS, Vredenburgh JJ.

J Clin Oncol. 2011 Oct 1;29(28):e739-42. doi: 10.1200/JCO.2011.36.1865. Epub 2011 Sep 6. No abstract available.

PMID:
21900098
26.

Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors.

Swisher CB, Doreswamy M, Gingrich KJ, Vredenburgh JJ, Kolls BJ.

Neurocrit Care. 2012 Feb;16(1):109-13. doi: 10.1007/s12028-011-9626-4.

PMID:
21882056
27.

Everolimus tablets for patients with subependymal giant cell astrocytoma.

Turner SG, Peters KB, Vredenburgh JJ, Desjardins A, Friedman HS, Reardon DA.

Expert Opin Pharmacother. 2011 Oct;12(14):2265-9. doi: 10.1517/14656566.2011.601742. Epub 2011 Aug 1. Review.

28.

Bevacizumab and daily temozolomide for recurrent glioblastoma.

Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE 2nd, Bailey L, Peters KB, Friedman HS, Vredenburgh JJ.

Cancer. 2012 Mar 1;118(5):1302-12. doi: 10.1002/cncr.26381. Epub 2011 Jul 26.

29.

Primary meningeal rhabdomyosarcoma.

Palta M, Riedel RF, Vredenburgh JJ, Cummings TJ, Green S, Chang Z, Kirkpatrick JP.

Sarcoma. 2011;2011:312802. doi: 10.1155/2011/312802. Epub 2011 Jun 23.

30.

Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.

Mitchell DA, Cui X, Schmittling RJ, Sanchez-Perez L, Snyder DJ, Congdon KL, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Sampson JH.

Blood. 2011 Sep 15;118(11):3003-12. doi: 10.1182/blood-2011-02-334565. Epub 2011 Jul 18.

31.

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.

Reardon DA, Vredenburgh JJ, Coan A, Desjardins A, Peters KB, Gururangan S, Sathornsumetee S, Rich JN, Herndon JE, Friedman HS.

J Neurooncol. 2011 Dec;105(3):621-7. doi: 10.1007/s11060-011-0631-4. Epub 2011 Jul 9.

32.

A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.

Desjardins A, Reardon DA, Peters KB, Threatt S, Coan AD, Herndon JE 2nd, Friedman AH, Friedman HS, Vredenburgh JJ.

J Neurooncol. 2011 Dec;105(3):601-6. doi: 10.1007/s11060-011-0627-0. Epub 2011 Jul 7.

PMID:
21735117
33.

Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.

Ruden E, Reardon DA, Coan AD, Herndon JE 2nd, Hornsby WE, West M, Fels DR, Desjardins A, Vredenburgh JJ, Waner E, Friedman AH, Friedman HS, Peters KB, Jones LW.

J Clin Oncol. 2011 Jul 20;29(21):2918-23. doi: 10.1200/JCO.2011.34.9852. Epub 2011 Jun 20.

34.

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.

Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Coan A, Threatt S, Friedman AH, Friedman HS.

Cancer. 2011 Dec 1;117(23):5351-8. doi: 10.1002/cncr.26188. Epub 2011 May 16.

35.

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.

Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE 2nd, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD, Friedman HS.

Clin Cancer Res. 2011 Jun 15;17(12):4119-24. doi: 10.1158/1078-0432.CCR-11-0120. Epub 2011 Apr 29.

36.

Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.

Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, Friedman HS, Willett CG, Kirkpatrick JP.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2018-24. doi: 10.1016/j.ijrobp.2010.12.074. Epub 2011 Apr 12.

37.

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

Reardon DA, Turner S, Peters KB, Desjardins A, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Jones LW, Kirkpatrick JP, Friedman AH, Vredenburgh JJ, Bigner DD, Friedman HS.

J Natl Compr Canc Netw. 2011 Apr;9(4):414-27. Review.

38.

A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme.

Paldino MJ, Desjardins A, Friedman HS, Vredenburgh JJ, Barboriak DP.

Br J Radiol. 2012 Apr;85(1012):382-9. doi: 10.1259/bjr/24774491. Epub 2011 Jan 11.

39.

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.

Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, Vredenburgh JJ, Bigner DD, Heimberger AB.

Neuro Oncol. 2011 Mar;13(3):324-33. doi: 10.1093/neuonc/noq157. Epub 2010 Dec 10.

40.

Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.

Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS.

Oncologist. 2010;15(12):1329-34. doi: 10.1634/theoncologist.2010-0105. Epub 2010 Dec 8.

41.

Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.

Vredenburgh JJ, Desjardins A, Kirkpatrick JP, Reardon DA, Peters KB, Herndon JE 2nd, Marcello J, Bailey L, Threatt S, Sampson J, Friedman A, Friedman HS.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):58-66. doi: 10.1016/j.ijrobp.2010.08.058. Epub 2010 Oct 30.

PMID:
21036490
42.

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE 2nd, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, Bigner DD.

J Clin Oncol. 2010 Nov 1;28(31):4722-9. doi: 10.1200/JCO.2010.28.6963. Epub 2010 Oct 4.

43.

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.

Reardon DA, Desjardins A, Peters K, Gururangan S, Sampson J, Rich JN, McLendon R, Herndon JE 2nd, Marcello J, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS.

J Neurooncol. 2011 Jun;103(2):371-9. doi: 10.1007/s11060-010-0403-6. Epub 2010 Sep 19.

44.

Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report.

Peters KB, McLendon R, Morse MA, Vredenburgh JJ.

Case Rep Oncol. 2010 Apr 8;3(1):93-97.

45.

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.

Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich JN, Norfleet JA, Gururangan S, Friedman HS, Reardon DA.

Neuro Oncol. 2010 Dec;12(12):1300-10. doi: 10.1093/neuonc/noq099. Epub 2010 Aug 17.

46.

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study.

Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR, Reardon DA, Prados MD.

Neuro Oncol. 2010 Oct;12(10):1061-70. doi: 10.1093/neuonc/noq072. Epub 2010 Jul 8.

47.

Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy.

Peters KB, Coyle TE, Vredenburgh JJ, Desjardins A, Friedman HS, Reardon DA.

J Neurooncol. 2011 Jan;101(1):155-9. doi: 10.1007/s11060-010-0239-0. Epub 2010 Jun 4.

PMID:
20524043
48.

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.

Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, Marcello J, Herndon JE 2nd, McLendon RE, Janney D, Friedman AH, Bigner DD, Friedman HS.

J Neurooncol. 2011 Jan;101(1):57-66. doi: 10.1007/s11060-010-0217-6. Epub 2010 May 5.

49.

Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration.

Aliabadi H, Vredenburgh JJ, Everson RG, Desjardins A, Friedman HS, McLendon RE, Tucci DL, Sampson JH.

J Neurooncol. 2010 Jul;98(3):427-30. doi: 10.1007/s11060-009-0091-2. Epub 2009 Dec 19.

PMID:
20020179
50.

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.

Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE 2nd, Marcello JE, Norfleet J, Friedman AH, Bigner DD, Friedman HS.

Br J Cancer. 2009 Dec 15;101(12):1986-94. doi: 10.1038/sj.bjc.6605412. Epub 2009 Nov 17.

Supplemental Content

Loading ...
Support Center